Forty one (14.2%) of 288 patients with primary intracerebral haemorrhage occurring between September 1985 and December 1989 in Central Finland were on anticoagulant treatment at the onset of symptoms. In a sample of 29 000 subjects from the same population the prevalence of anticoagulant treatment was 1-6% in those aged 40 years or older. The estimated age adjusted odds ratio of being on anti-coagulant treatment at the time of primary intracerebral haemorrhage was 6-7 (95% CI from 4*5 to 9.9). The risk was highest during the first year of anticoagulation. Overtreatment (thrombotest value < 5%) was slightly more common among the patients. The haematoma volumes measured from the CT scans were similar in patients on anticoagulant treatment and those not anticoagulated. The case fatality rate during the first week and the mortality during foliow up of 32 months were slightly higher, and the functional outcome slighdy worse in the anticoagulated group. 9%-23%.28 There are two studies8 9 in which the magnitude of the risk of intracerebral haemorrhage during AC treatment has been estimated as 7 6-1 1 times higher than that of patients not on AC treatment. In addition, factors possiblycontributing to this increased risk have been identified, for example, the level of anticoagulation, the duration of the AC treatment, and hypertension.
Bleeding complications are inherent risks of anticoagulant (AC) treatment and most of the fatal bleedings are intracranial.' In studies on spontaneous intracerebral haemorrhage during the era of CT the prevalence of patients being on AC treatment at the onset of bleeding has varied from 9%-23%.28
There are two studies8 9 in which the magnitude of the risk of intracerebral haemorrhage during AC treatment has been estimated as 7 6-1 1 times higher than that of patients not on AC treatment. In addition, factors possiblycontributing to this increased risk have been identified, for example, the level of anticoagulation, the duration of the AC treatment, and hypertension.
The aim of this retrospective study was to estimate the magnitude of the increased risk of primary intracerebral haemorrhage (PICH) during AC treatment, and to find out factors possibly associated with this risk. The study was based on a representative patient material with either CT or necropsy confirmation of the diagnosis, and on prevalence data of AC treatment in a sample of the same population from which the patients emerged. In addition, we compared the haematoma volumes and the outcome of patients on those not anticoagulated.
AC treatment with
Patients and methods During the period from 1 September 1985 to 31 December 1989 a total of 293 patients with PICH were diagnosed in a population of 245 000 in Central Finland (fig 1) . The diagnosis was confirmed in 237 cases by CT, and in 56 cases by necropsy. Of these patients 158 have been included in an epidemiological study on the population of 116 000 living in the Jyvaskyla Region,10 the other 135 patients are from other parts of Central Finland. The patients in this study were traced from: a) files of the Department of Neurology; b) discharge lists of the Central Hospital, the Health Centres, and the Department of Neurosurgery, University of Kuopio; c) lists of death certificates of Central Finland, and d) medical and medico-legal necropsy reports. The diagnosis of PICH excludes haemorrhages due to trauma, rupture of an arterial aneurysm or arterio-venous malformation, or bleeding from cerebral neoplasm.
On the basis of the figures from the epidemiological study from the Jyvaskyla Region'0 we estimated that 90% of all PICH cases aged less than 69 years, 71% aged 70-79 years, and 50% aged 80 years or more that occurred in Central Finland during the study period were included in our analysis. Data on AC treatment, previous hypertension, stroke, and cardiac diseases was obtained in 288 patients which form the basis of this study.
The CT examinations were performed within 24 hours of onset in 43%, and within 72 hours in 90% of the patients. The location of the haematomas on the CT films was assessed applying the anatomical atlas of Kretschmann and Weinrich. "l The haematoma volumes were measured from the CT films using a computer program. The area of the haemorrhage in each slice was measured planimetrically and multiplied by the thickness of the slice. The sum of these subvolumes gave the total haematoma volume.
At the end of follow up (31 August 1990) all patients who had been discharged alive were contacted by telephone, or in the case of death or severe handicap a relative or carer was interviewed. The functional outcome was assessed using the Rankin grading system,'2 and the cause of death obtained from the death certificates was confirmed by data from the medical and necropsy records. 
The average duration of AC treatment of patients with PICH was shorter than in the population; 44% of the PICH patients had been on AC treatment for less than 1 year, half of these for less than 4 months, compared with 19% of the population sample (fig 2) . Conversely, long-term treatment (> 5 years) was more common in the population sample. The trend was statistically highly significant (X = 19-0 df= 5 p = 0002).
The most recent thrombotest before onset of PICH was measured in 76% of patients within two weeks, most often on the day of onset. Overtreatment (thrombotest < 5%) was slightly more common among PICH patients (4/41) than among the population sample (6/208) X2 = 4-2 p = 004).
Lobar and posterior fossa haematomas were slightly more frequent in PICH patients on AC treatment but deep basal ganglionic haematomas were more common in patients not on AC treatment. Twenty seven (66%) of the AC (n = 27 r = 0-14 p = 05). Coronary heart disease, congestive heart failure, atrial fibrillation, and ischaemic cerebrovascular disease were statistically significantly more prevalent in patients on AC treatment (table 4) , and was readily explained by selection due to the indications of anticoagulant treatment. The CT confirmed location of the previous ischaemic brain infarction was the same as the present haemorrhage in only 5/13 (38%) of the cases.
The case fatality rate during the first week after onset was 54% among the AC treated, and 40% among the non-anticoagulated, and after a median follow up of 32 months was 71% of the AC treated, and 61% of those nonanticoagulated. The differences were nonsignificant. The functional outcome at the end of follow up, assessed by the Rankin grading system was similar in both patient groups, half of the patients being independent (Ranking groups 1 and 2) in the ADL. Poor outcome (Ranking grade 5) was, however, more common among the AC treated than the nonanticoagulated (2/12 and 4/97), a statistically non-significant difference.
Discussion 1 Comparison with population data
The 288 PICH patients included in this study can be considered fairly representative of the disease as it occurs in the population, especially in those under the age of 80 years. A more difficult question is how well the chosen population sample from the three Health Centres represents the population of Central Finland. Because the distribution of the indications of anticoagulant treatment and the thrombotest values were quite similar in these Health Centres it is assumed that they are a fairly good representation of the whole of Central Finland, the catchment area of the Central Hospital. On the other hand, the age and sex adjusted prevalence rates of AC treatment for those aged 40 years or over varied between 1-14% and 1-88% in the chosen Health Centres, and this indicates the presence of possible differences in the use of anticoagulants.
The age adjusted OR 6-7 obtained in our study agrees with earlier reports.8 9 Age had no impact on the ORs, as previously reported. 8 The duration of the AC treatment was more often less than 1 The trend of poorer short and long-term survival and fimctional outcome of the AC treated patients confirms the earlier observations.89 In one study the case fatality rate of the anticoagulated patients was even twice that of the non-anticoagulated. 7 To minimise the risk of PICH during AC treatment the indications for starting treatment should be stringent. Overtreatment should be avoided, and the duration of the treatment should be as short as possible.'9 Low intensity anticoagulation might also significantly reduce the number of intracerebral haemorrhages,20 and in elderly patients all contraindications, concomitant diseases, and medications should be carefully considered.2' 22 If the patient, however, suffers from a PICH, the outcome seems no worse than in patients without AC treatment.
